This was a multicenter cohort study performed across 9 hospitals (2 tertiary care and 7 community hospitals) in Massachusetts. All consecutive adults (age ≥18 years) hospitalized on or before April 2, 2020, were included. Only patients with laboratory-confirmed SARS-CoV-2 on polymerase chain reaction nasopharyngeal swab testing were included. Patient demographics; presenting systemic, respiratory, and gastrointestinal symptoms; comorbid conditions; laboratory data; and clinically relevant hospitalization outcomes (including intensive care unit (ICU) admission, need for mechanical ventilation, and in-hospital mortality) were obtained. The primary outcome was prevalence of any gastrointestinal symptoms in patients hospitalized with COVID-19 at initial presentation. Secondary analyses included associations between gastrointestinal symptoms and other clinical manifestations, laboratory results, patient characteristics, and hospital course.
Liver injury has been described with COVID‐19, and early reports suggested 2%‐11% of patients had chronic liver disease (CLD). In this multicentre retrospective study, we evaluated hospitalized adults with laboratory‐confirmed COVID‐19 and the impact of CLD on relevant clinical outcomes. Of 363 patients included, 19% had CLD, including 15.2% with NAFLD. Patients with CLD had longer length of stay. After controlling for age, gender, obesity, cardiac diseases, hypertension, hyperlipidaemia, diabetes and pulmonary disorders, CLD and NAFLD were independently associated with ICU admission ([aOR 1.77, 95% CI 1.03‐3.04] and [aOR 2.30, 95% CI 1.27‐4.17]) and mechanical ventilation ([aOR 2.08, 95% CI 1.20‐3.60] and [aOR 2.15, 95% CI 1.18‐3.91]). Presence of cirrhosis was an independent predictor of mortality (aOR 12.5, 95% CI 2.16‐72.5). Overall, nearly one‐fifth of hospitalized COVID‐19 patients had CLD, which was associated with more critical illness. Future studies are needed to identify interventions to improve clinical outcomes.
INTRODUCTION: Divergent recommendations for periprocedural management of glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA) medications rely on limited evidence. We performed a systematic review and meta-analysis to provide quantitative measures of gastric emptying relevant to mechanisms of weight loss and to periprocedural management of GLP-1 RA. We hypothesized that the magnitude of gastric emptying delay would be low and of limited clinical significance to procedural sedation risks. METHODS: A protocolized search identified studies on GLP-1 RA that quantified gastric emptying measures. Pooled estimates using random effects were presented as a weighted mean difference with 95% confidence intervals (CIs). Univariate meta-regression was performed to assess the influence of GLP-1 RA type, short-acting vs long-acting mechanism of action, and duration of treatment on gastric emptying. RESULTS: Fifteen studies met the inclusion criteria. Five studies (n = 247) utilized gastric emptying scintigraphy. Mean T1/2 was 138.4 minutes (95% CI 74.5–202.3) for GLP-1 RA vs 95.0 minutes (95% CI 54.9–135.0) for placebo, with a pooled mean difference of 36.0 minutes (95% CI 17.0–55.0, P < 0.01, I2 = 79.4%). Ten studies (n = 411) utilized the acetaminophen absorption test, with no significant delay in gastric emptying measured by Tmax, area under the curve (AUC)4hr, and AUC5hr with GLP-1 RA (P > 0.05). On meta-regression, the type of GLP-1 RA, mechanism of action, and treatment duration did not impact gastric emptying (P > 0.05). DISCUSSION: While a gastric emptying delay of ∼36 minutes is quantifiable on GLP-1 RA medications, it is of limited magnitude relative to standard periprocedural fasting periods. There were no substantial differences in gastric emptying on modalities reflective of liquid emptying (acetaminophen absorption test), particularly at time points relevant to periprocedural care.